Michael Fries

Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B

P. Monahan, M. Fries, Hongseok Kim, 2022, Current medical research and opinion.

The Effect of Alpha-1 Proteinase Inhibitor on Biomarkers of Elastin Degradation in Alpha-1 Antitrypsin Deficiency: An Analysis of the RAPID/RAPID Extension Trials.

G. Turino, J. Edelman, R. Sandhaus, 2016, Chronic obstructive pulmonary diseases.

Aggregate Safety Assessment Planning for the Drug Development Life-Cycle

Greg Ball, Barbara A Hendrickson, William Wang, 2021, Therapeutic Innovation & Regulatory Science.

Safety of biweekly α1-antitrypsin treatment in the RAPID programme

T. Greulich, C. Vogelmeier, N. McElvaney, 2018, European Respiratory Journal.

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).

M. Sanak, J. Ficker, N. Seersholm, 2017, The Lancet. Respiratory medicine.

Increased proportion of slow decliners in patients with alpha-1 protease inhibitor (A1-PI) deficiency following treatment with A1-PI

N. Seersholm, K. Chapman, M. Wencker, 2016 .